Cargando…

Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center

Background Pulmonary toxicity due to chemotherapeutic agents can occur with many established and new drugs. Strong clinical suspicion is important as the clinical presentation is usually with nonspecific symptoms like cough, dyspnea, fever, and pulmonary infiltrates. Timely discontinuation of the of...

Descripción completa

Detalles Bibliográficos
Autores principales: TVSVGK, Tilak, Handa, Ajay, Kumar, Kishore, Mutreja, Deepti, Subramanian, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Private Ltd 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719973/
https://www.ncbi.nlm.nih.gov/pubmed/34984206
http://dx.doi.org/10.1055/s-0041-1731581
_version_ 1784625052131524608
author TVSVGK, Tilak
Handa, Ajay
Kumar, Kishore
Mutreja, Deepti
Subramanian, Shankar
author_facet TVSVGK, Tilak
Handa, Ajay
Kumar, Kishore
Mutreja, Deepti
Subramanian, Shankar
author_sort TVSVGK, Tilak
collection PubMed
description Background Pulmonary toxicity due to chemotherapeutic agents can occur with many established and new drugs. Strong clinical suspicion is important as the clinical presentation is usually with nonspecific symptoms like cough, dyspnea, fever, and pulmonary infiltrates. Timely discontinuation of the offending agent alone can improve the condition. Methods A prospective observational study on patients receiving chemotherapy at an 800-bedded tertiary care hospital was performed from 2014 to 2016. Consecutive patients on chemotherapy, presenting with nonresolving respiratory symptoms were evaluated with contrast-enhanced computerized tomography of chest, diffusion lung capacity for carbon monoxide (DLCO), fiberoptic bronchoscopy with lavage, and biopsy, after excluding all causes for pulmonary infections. Descriptive data has been depicted. Results A total of 18 patients were evaluated for persistent symptoms of dry cough, dyspnea, and fever among 624 who received chemotherapy during the study period. Ground-glass opacities on high-resolution CT was the most common imaging finding, others being patchy subpleural consolidation and pleural effusion. Lymphocyte-predominant bronchoalveolar lavage was detected in nine. Eight of the 15 patients who underwent DLCO, had abnormal results. Seven had significant histopathological findings on bronchoscopic lung biopsy, which revealed organizing pneumonia as the most common pattern. Paclitaxel, fluorouracil, gemcitabine, and tyrosine kinase inhibitors were the common culprit drugs. Discontinuation alone of the culprit drug was effective in 15 and 3 needed oral corticosteroids for relief of symptoms. None of the patients died due to the toxicity. Conclusion An incidence of 2.8% for chemotherapy-induced lung injury was seen in our observational study of 3 years, with parenchymal, interstitial, and pleural involvement due to various chemotherapeutic agents. Oral steroids maybe required in a subset of patients not responding to discontinuation of the culprit agent.
format Online
Article
Text
id pubmed-8719973
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Thieme Medical and Scientific Publishers Private Ltd
record_format MEDLINE/PubMed
spelling pubmed-87199732022-01-03 Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center TVSVGK, Tilak Handa, Ajay Kumar, Kishore Mutreja, Deepti Subramanian, Shankar South Asian J Cancer Background Pulmonary toxicity due to chemotherapeutic agents can occur with many established and new drugs. Strong clinical suspicion is important as the clinical presentation is usually with nonspecific symptoms like cough, dyspnea, fever, and pulmonary infiltrates. Timely discontinuation of the offending agent alone can improve the condition. Methods A prospective observational study on patients receiving chemotherapy at an 800-bedded tertiary care hospital was performed from 2014 to 2016. Consecutive patients on chemotherapy, presenting with nonresolving respiratory symptoms were evaluated with contrast-enhanced computerized tomography of chest, diffusion lung capacity for carbon monoxide (DLCO), fiberoptic bronchoscopy with lavage, and biopsy, after excluding all causes for pulmonary infections. Descriptive data has been depicted. Results A total of 18 patients were evaluated for persistent symptoms of dry cough, dyspnea, and fever among 624 who received chemotherapy during the study period. Ground-glass opacities on high-resolution CT was the most common imaging finding, others being patchy subpleural consolidation and pleural effusion. Lymphocyte-predominant bronchoalveolar lavage was detected in nine. Eight of the 15 patients who underwent DLCO, had abnormal results. Seven had significant histopathological findings on bronchoscopic lung biopsy, which revealed organizing pneumonia as the most common pattern. Paclitaxel, fluorouracil, gemcitabine, and tyrosine kinase inhibitors were the common culprit drugs. Discontinuation alone of the culprit drug was effective in 15 and 3 needed oral corticosteroids for relief of symptoms. None of the patients died due to the toxicity. Conclusion An incidence of 2.8% for chemotherapy-induced lung injury was seen in our observational study of 3 years, with parenchymal, interstitial, and pleural involvement due to various chemotherapeutic agents. Oral steroids maybe required in a subset of patients not responding to discontinuation of the culprit agent. Thieme Medical and Scientific Publishers Private Ltd 2021-11-11 /pmc/articles/PMC8719973/ /pubmed/34984206 http://dx.doi.org/10.1055/s-0041-1731581 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle TVSVGK, Tilak
Handa, Ajay
Kumar, Kishore
Mutreja, Deepti
Subramanian, Shankar
Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center
title Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center
title_full Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center
title_fullStr Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center
title_full_unstemmed Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center
title_short Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center
title_sort chemotherapy-associated pulmonary toxicity—case series from a single center
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719973/
https://www.ncbi.nlm.nih.gov/pubmed/34984206
http://dx.doi.org/10.1055/s-0041-1731581
work_keys_str_mv AT tvsvgktilak chemotherapyassociatedpulmonarytoxicitycaseseriesfromasinglecenter
AT handaajay chemotherapyassociatedpulmonarytoxicitycaseseriesfromasinglecenter
AT kumarkishore chemotherapyassociatedpulmonarytoxicitycaseseriesfromasinglecenter
AT mutrejadeepti chemotherapyassociatedpulmonarytoxicitycaseseriesfromasinglecenter
AT subramanianshankar chemotherapyassociatedpulmonarytoxicitycaseseriesfromasinglecenter